ライフサイエンスコーパス: neuropsychiatric

1 rom two main disease classes, autoimmune and neuropsychiatric.

2 generally well tolerated, with low rates of neuropsychiatric AEs.

3 dysfunction has been implicated in numerous neuropsychiatric ailments.

4 b BP2-BP3 CNV is likewise a potent driver of neuropsychiatric, anatomical, and metabolic pathologies.

5 Palmitoylation is involved in several neuropsychiatric and movement disorders for which a dysf

6 y are associated with drug abuse, as well as neuropsychiatric and movement disorders.

7 procedures of the effort to characterize the neuropsychiatric and neurobehavioral phenotypes associat

8 ul approach to prevent cognitive deficits in neuropsychiatric and neurocognitive disorders that are a

9 Many debilitating neuropsychiatric and neurodegenerative disorders are cha

10 Several neuropsychiatric and neurodegenerative disorders share s

11 Tourette Disorder (TD) is a childhood-onset neuropsychiatric and neurodevelopmental disorder charact

12 plays a significant part in the etiology of neuropsychiatric and neurodevelopmental disorders.

13 Several neuropsychiatric and neurological disorders have recentl

14 ve comorbidities, and may extend to multiple neuropsychiatric and neurological disorders in which REL

15 o guide appropriate behavior is disrupted in neuropsychiatric and neurological disorders including de

16 zures; are often accompanied by debilitating neuropsychiatric and systemic comorbidities; and carry a

17 estigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HR

18 e with comprehensive longitudinal cognitive, neuropsychiatric, and HRQoL assessments.

19 Associations with cardiovascular, neuropsychiatric, and malignant diseases were increasing

20 cal features, such as autonomic dysfunction, neuropsychiatric changes, viral prodrome, faciobrachial

21 nd further, could account for aspects of the neuropsychiatric clinical sequelae reported.

22 ury and stroke, and is often associated with neuropsychiatric comorbidities.

23 Developmental stuttering is a neuropsychiatric condition of incompletely understood br

24 based on the number of family members with a neuropsychiatric condition: expected (0-2) and high (>/=

25 ands (17.2%) with a strong family history of neuropsychiatric conditions (>/=3 first-degree or second

26 mechanisms underlying social dysfunction in neuropsychiatric conditions such as obsessive-compulsive

27 n extends to social performance as occurs in neuropsychiatric conditions such as OCD and TS.

28 To examine the frequency and range of neuropsychiatric conditions that occur within individual

29 evidence suggests a role for inflammation in neuropsychiatric conditions, including autism spectrum d

30 Several neuropsychiatric conditions, such as addiction and schiz

31 The involvement of mGluR2/3 in other neuropsychiatric conditions, such as anxiety, depression

32 gically informed treatment strategies across neuropsychiatric conditions.

33 gnitive control and is implicated in several neuropsychiatric conditions.

34 thways that underlie diagnostically distinct neuropsychiatric conditions.

35 social norms is compromised in a variety of neuropsychiatric conditions.

36 al comorbidities often seen in ASD and other neuropsychiatric conditions.

37 ing dysfunctional decision-making related to neuropsychiatric conditions.

38 rify the involvement of TBL1XR1 mutations in neuropsychiatric conditions.

39 elopment that could improve several comorbid neuropsychiatric conditions.

40 mic activity subtending the symptoms of some neuropsychiatric conditions.

41 in 45,376 exomes from individuals without a neuropsychiatric diagnosis, indicating that SETD1A is su

42 letions and duplications of 15q13.3 manifest neuropsychiatric disease and cognitive deficits.

43 s how these data inform our understanding of neuropsychiatric disease and discuss the potential role

44 come and Measures: The prevalence of defined neuropsychiatric disease in first-degree and second-degr

45 eiotropic genes associated with both ALS and neuropsychiatric disease in the Irish population.

46 ding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to

47 romising avenue for therapeutic targeting in neuropsychiatric disease states.

48 Some neuropsychiatric disease, including schizophrenia, may o

49 contribute to the propensity for developing neuropsychiatric disease, including substance abuse diso

50 abnormal kidney and muscle development, and neuropsychiatric disease, this Fat1 function may have im

51 erstanding of the regulome and the impact of neuropsychiatric disease-associated genetic risk variant

52 transcriptional mechanisms that may underlie neuropsychiatric disease.

53 indles may represent heritable biomarkers of neuropsychiatric disease.

54 olding protein that has been associated with neuropsychiatric disease.

55 lt offspring brain, mimicking those in human neuropsychiatric disease.

56 ge at the level of the glia to contribute to neuropsychiatric disease.

57 al quantitative variation and in relation to neuropsychiatric disease.

58 anifestation of a broader pattern of chronic neuropsychiatric disease.

59 e functional relevance of such regulation to neuropsychiatric disease.

60 tation-transcription coupling both relate to neuropsychiatric disease.

61 ological basis of reward- and stress-related neuropsychiatric disease.

62 for future translational relevance to human neuropsychiatric disease.

63 s associated with neurological disorders and neuropsychiatric disease.

64 r loss or dysfunction is implicated in human neuropsychiatric disease.

65 n for aggression arising in certain forms of neuropsychiatric disease.

66 linical trials for potential use in treating neuropsychiatric diseases and drug addictions.

67 echanistic insight to the processes by which neuropsychiatric diseases at a young age affect the risk

68 essential to developing novel therapies for neuropsychiatric diseases such as OCD and ASDs with Hoxb

69 hese findings could provide new insight into neuropsychiatric diseases that involve improper generali

70 sychomotor" syndrome that is observed across neuropsychiatric diseases, have remained obscure.

71 eceptors have been used to treat a number of neuropsychiatric diseases, including alcoholism.

72 cated in various developmental processes and neuropsychiatric diseases, its role in neurodevelopment

73 ssociated with certain neurodegenerative and neuropsychiatric diseases.

74 ealing mitochondrial defects associated with neuropsychiatric diseases.

75 d framework for future analyses of miRNAs in neuropsychiatric diseases.

76 an emerging therapy for diverse, refractory neuropsychiatric diseases.

77 thogenesis of a wide range of neurologic and neuropsychiatric diseases.

78 Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder associated with significant im

79 Tourette syndrome (TS) is a neuropsychiatric disorder characterized by multiple tics

80 ed in obsessive compulsive disorder (OCD), a neuropsychiatric disorder characterized by the execution

81 Anorexia nervosa (AN) is a complex neuropsychiatric disorder presenting with dangerously lo

82 IGNIFICANCE STATEMENT Cocaine addiction is a neuropsychiatric disorder that is detrimental to society

83 Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal

84 Schizophrenia is a debilitating neuropsychiatric disorder typically diagnosed from late

85 s de la Tourette syndrome (GTS) is a complex neuropsychiatric disorder with a strong genetic influenc

86 Schizophrenia is a chronic, disabling neuropsychiatric disorder with complex genetic origins.

87 ted.Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder with symptoms including intrus

88 common variants that increase the risk of a neuropsychiatric disorder, while there is growing eviden

89 suggested that defective microglia cause the neuropsychiatric disorder.

90 Bipolar affective disorder is a common neuropsychiatric disorder.

91 e pathogenesis and treatment of nearly every neuropsychiatric disorder.

92 can result in diagnosis with an ASD or other neuropsychiatric disorder.

93 ne encoding CaMKIIalpha linked to a specific neuropsychiatric disorder.

94 According to the depression-as-late-life-neuropsychiatric-disorder model, lower hippocampal volum

95 nd a wider spectrum of neurodegenerative and neuropsychiatric disorders among family members, includi

96 f chromosome 16 region 16p11.2 are linked to neuropsychiatric disorders and are among the most preval

97 regulation of neuronal function relevant to neuropsychiatric disorders and clarify the role of Kctd1

98 This capacity is vulnerable in neuropsychiatric disorders and in the aftermath of chron

99 ves executive functions that are impaired in neuropsychiatric disorders and pain.

100 variants is a key challenge in understanding neuropsychiatric disorders and will open an avenue in th

101 Persons with neuropsychiatric disorders are at increased risk of suic

102 Several neuropsychiatric disorders are characterized by heighten

103 Many neuropsychiatric disorders are marked by abnormal behavi

104 mGluR5 as a potential therapeutic target in neuropsychiatric disorders associated with abnormal nove

105 rders, a concept termed pediatric autoimmune neuropsychiatric disorders associated with streptococcal

106 SC technology to model and potentially treat neuropsychiatric disorders by focusing on the most preva

107 These results have implications for neuropsychiatric disorders characterized by accelerated

108 he field of neuropsychopharmacology, as many neuropsychiatric disorders exhibit gender bias in the fr

109 have been found unsuitable for treatment of neuropsychiatric disorders for reasons such as inability

110 ve functions in people with neurological and neuropsychiatric disorders has been a major goal of psyc

111 autoantibodies against neuronal receptors in neuropsychiatric disorders has fostered new conceptual a

112 t of the cholinergic system in cognitive and neuropsychiatric disorders in DLB patients.

113 tulates dimensional aspects of developmental neuropsychiatric disorders in mice.

114 mon and dissociable CBF abnormalities across neuropsychiatric disorders in youth.

115 ) in the brain has been detected in numerous neuropsychiatric disorders including Alzheimer's disease

116 merged as a candidate risk gene for multiple neuropsychiatric disorders including bipolar disorder, m

117 nctional mutations in known causal genes for neuropsychiatric disorders including holoprosencephaly a

118 rgic dysregulation characterizes a number of neuropsychiatric disorders including schizophrenia and a

119 ic factors underlying neurodevelopmental and neuropsychiatric disorders is a major challenge given th

120 ch a functional biomarker may be of value to neuropsychiatric disorders like bipolar and autism spect

121 Neuropsychiatric disorders place an enormous medical bur

122 e a neurogenetic framework for understanding neuropsychiatric disorders related to reproductive hormo

123 Targeted therapy for neuropsychiatric disorders requires selective modulation

124 treat social impairment in individuals with neuropsychiatric disorders such as autism.

125 ppetitive, and aversive behavior, as well as neuropsychiatric disorders such as Parkinson's disease,

126 White matter abnormalities are prevalent in neuropsychiatric disorders such as schizophrenia, but it

127 The high comorbidity among neuropsychiatric disorders suggests a possible common ne

128 ing normal brain development, as well as the neuropsychiatric disorders that emerge in this vulnerabl

129 e major diagnostic symptoms in a spectrum of neuropsychiatric disorders that include schizophrenia, o

130 AS signals for common diseases, ranging from neuropsychiatric disorders to cancers.

131 To better understand the role of CREs in neuropsychiatric disorders we applied the Assay for Tran

132 or pharmacological manipulation of Cav1.2 in neuropsychiatric disorders with developmental and/or str

133 of chromosome 15q13.3 manifest clinically as neuropsychiatric disorders with variable expressivity.

134 smokers (mean age = 25 years; no history of neuropsychiatric disorders), following an overnight peri

135 coexpressed networks of genes implicated in neuropsychiatric disorders, and the expression of these

136 y an invertebrate organism in the context of neuropsychiatric disorders, and we discuss how we can ga

137 f human infections and neurodegenerative and neuropsychiatric disorders, animal models of BDV infecti

138 understanding of the genetic architecture of neuropsychiatric disorders, but it has also led to a bro

139 Like other neuropsychiatric disorders, depression is not a unitary

140 nd their ligands are associated with diverse neuropsychiatric disorders, especially schizophrenia, au

141 epistatic events and genetic interactions in neuropsychiatric disorders, how paradigm shifts in the p

142 d amphetamine-and plays an important role in neuropsychiatric disorders, including attention-deficit

143 y patterns between resting state networks in neuropsychiatric disorders, including Autism Spectrum Di

144 ellitus, and autoimmune disorders as well as neuropsychiatric disorders, including autism, anxiety, a

145 ess affected in a number of neurological and neuropsychiatric disorders, including fragile X syndrome

146 is characteristically disrupted in multiple neuropsychiatric disorders, including major depressive d

147 essed throughout limbic circuits affected in neuropsychiatric disorders, including prefrontal cortex

148 e decision making is associated with several neuropsychiatric disorders, including problem gambling a

149 C spontaneous default activity is altered in neuropsychiatric disorders, including schizophrenia-a di

150 been associated with abnormal motivation in neuropsychiatric disorders, including schizophrenia.

151 a genetic risk factor for developing several neuropsychiatric disorders, including schizophrenia.

152 nd are implicated in the etiology of several neuropsychiatric disorders, including substance use diso

153 itical role in health and disease, including neuropsychiatric disorders, is rapidly advancing.

154 2 receptor (D2R) activity is associated with neuropsychiatric disorders, making those receptors targe

155 rd hypersensitization is a common feature of neuropsychiatric disorders, manifesting as impulsivity f

156 stem are linked to multiple neurological and neuropsychiatric disorders, many of which present with s

157 , as characterized by neurodevelopmental and neuropsychiatric disorders, neuromuscular and neurodegen

158 a promising biomarker of susceptibility for neuropsychiatric disorders, particularly because of its

159 he risk for offspring neurodevelopmental and neuropsychiatric disorders, prompting critical examinati

160 in the fields of human neurodegenerative and neuropsychiatric disorders, such as Huntington's disease

161 In many neurodevelopmental and neuropsychiatric disorders, the excitability of local ci

162 uring pregnancy have each been implicated in neuropsychiatric disorders, whether and how these presum

163 r incidence is among the most extreme of all neuropsychiatric disorders, yet the origins of the sex d

164 replicable susceptibility genes for several neuropsychiatric disorders.

165 nction in specific subtypes is implicated in neuropsychiatric disorders.

166 dissection of neural circuits implicated in neuropsychiatric disorders.

167 variants have been reported in patients with neuropsychiatric disorders.

168 ations of the two can be sufficient to cause neuropsychiatric disorders.

169 o behavioural and health outcomes, including neuropsychiatric disorders.

170 approaches for the treatment of a variety of neuropsychiatric disorders.

171 d to discover unknown neuronal phenotypes of neuropsychiatric disorders.

172 ion molecules implicated in autism and other neuropsychiatric disorders.

173 te aspects of the psychopathology of several neuropsychiatric disorders.

174 viously implicated in neurodevelopmental and neuropsychiatric disorders.

175 ritis, inflammatory bowel diseases, and even neuropsychiatric disorders.

176 ber variation (CNV) is an important cause of neuropsychiatric disorders.

177 into the imbalance of brain states found in neuropsychiatric disorders.

178 functions and is critically involved in many neuropsychiatric disorders.

179 increases risk for complex traits, including neuropsychiatric disorders.

180 ion of SWI/SNF-regulated genes implicated in neuropsychiatric disorders.

181 s increased risk for a range of debilitating neuropsychiatric disorders.

182 iscussing ways to consider sex when studying neuropsychiatric disorders.

183 volume and shape are found in several common neuropsychiatric disorders.

184 of resting-state networks (RSNs) in several neuropsychiatric disorders.

185 atory variants across neurodevelopmental and neuropsychiatric disorders.

186 rain as well as its potential involvement in neuropsychiatric disorders.

187 ial survival mechanism often dysregulated in neuropsychiatric disorders.

188 ighest known genetic risks for developmental neuropsychiatric disorders.

189 upted as part of the pathophysiology of many neuropsychiatric disorders.

190 brain and behavioral phenotypes relevant to neuropsychiatric disorders.

191 ating their impact on neurodevelopmental and neuropsychiatric disorders.

192 naling-associated genes, have been linked to neuropsychiatric disorders.

193 rol processes and is dysregulated in several neuropsychiatric disorders.

194 f neurodevelopmental, neurodegenerative, and neuropsychiatric disorders.

195 expression may be differentially altered in neuropsychiatric disorders.

196 binoid signaling are associated with various neuropsychiatric disorders.

197 ould contribute to a range of neurologic and neuropsychiatric disorders.

198 Ca(2+) signalling to the pathophysiology of neuropsychiatric disorders.

199 de or too narrow generalization is linked to neuropsychiatric disorders.

200 terizations in the differential diagnosis of neuropsychiatric disorders.

201 terizing deficits and refining treatments in neuropsychiatric disorders.

202 the brain, and are an intriguing target for neuropsychiatric disorders.

203 implicated in the pathophysiology of several neuropsychiatric disorders.

204 nd social behavioral disturbances present in neuropsychiatric disorders.

205 ptor is an attractive therapeutic target for neuropsychiatric disorders.

206 may underlie pathophysiology associated with neuropsychiatric disorders.

207 ments of candidate genes in the pathology of neuropsychiatric disorders.

208 ctors contributing to neurodevelopmental and neuropsychiatric disorders.

209 it and which is vulnerable to impairments in neuropsychiatric disorders.

210 e pathophysiology of an increasing number of neuropsychiatric disorders.

211 ant spine morphology is associated with many neuropsychiatric disorders.

212 lator with known links to a wide spectrum of neuropsychiatric disorders.

213 tions for our understanding and treatment of neuropsychiatric disorders.

214 malities in regional CBF are present in many neuropsychiatric disorders.

215 in shaping the overall phenotypes of genetic neuropsychiatric disorders.

216 n (OT) is a potential treatment for multiple neuropsychiatric disorders.

217 d objectively defining subtypes within other neuropsychiatric disorders.

218 impacted during the course of developmental neuropsychiatric disorders.

219 urons in emotional deficits portending major neuropsychiatric disorders.

220 whereby neuroligin-3 mutations contribute to neuropsychiatric disorders.

221 s, which are often observed in patients with neuropsychiatric disorders.

222 er role in cognition and its disturbances in neuropsychiatric disorders.

223 esistant epileptic seizures, and more severe neuropsychiatric disorders.

224 nificantly overlap with loci associated with neuropsychiatric disorders.

225 a vulnerable target of many neurological and neuropsychiatric disorders.

226 l process in the trajectory of developmental neuropsychiatric disorders.

227 rment in this development is associated with neuropsychiatric disorders.

228 nt role for integrins in modulating risk for neuropsychiatric disorders.SIGNIFICANCE STATEMENT The in

229 eved 17,104 DNMs from 3555 trios across four neuropsychiatric disorders: autism spectrum disorder, ep

230 In contrast, frequent use of neuropsychiatric drugs further increased after RYGB.

231 Use of neuropsychiatric drugs was two-fold higher at baseline i

232 oderate to severe ID, epilepsy, and variable neuropsychiatric features.

233 ng, clinical phenotypes, each also including neuropsychiatric features.

234 that are themselves also major regulators of neuropsychiatric function.

235 anscription factors are master regulators of neuropsychiatric function.

236 suggest a critical role for NPAS proteins in neuropsychiatric functioning, prompting interest in the

237 with regard to the therapeutic potential for neuropsychiatric health.

238 to DDC-mediated neural processes relevant to neuropsychiatric illness and treatment.

239 n influences hippocampal volume and risk for neuropsychiatric illness.

240 ance to understanding the pathophysiology of neuropsychiatric illness.

241 mperament traits have been linked to several neuropsychiatric illnesses, including disorders associat

242 or treatment response in complex, heritable neuropsychiatric illnesses.

243 pregnancy, whether for epilepsy or for other neuropsychiatric indications, are at a higher risk of de

244 dality on the suicidality module of the Mini Neuropsychiatric Interview (M.I.N.I) was 3.3% (95% CI, 2

245 The Mini Neuropsychiatric Interview was used to establish MDD.

246 ations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the firs

247 sychiatric symptoms were evaluated using the Neuropsychiatric Inventory (NPI).

248 opsychiatric symptom domains assessed by the Neuropsychiatric Inventory (NPI).

249 the Hamilton Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire.

250 hallucinations and agitation domains of the Neuropsychiatric Inventory) and extrapyramidal side effe

251 level on any of the other common somatic and neuropsychiatric outcomes investigated in the present st

252 Stress-related neuropsychiatric pathologies are more prevalent in femal

253 ne receptor (nAChR), and manifest a variable neuropsychiatric phenotype that frequently includes pers

254 mechanisms underlying the role of Cav1.3 in neuropsychiatric phenotypes are not well established.

255 lvement across a wide range of cognitive and neuropsychiatric phenotypes is increasingly being recogn

256 e of 5,720 Finnish exomes, both with notable neuropsychiatric phenotypes.

257 al to the function of CaV1.2 in synaptic and neuropsychiatric processes.

258 e a role of Cav1.3 L-type Ca(2+) channels in neuropsychiatric-related behaviors, such as addictive an

259 aberrant Cav1.2 signaling may contribute to neuropsychiatric-related disease symptoms via impaired P

260 study identifies a novel Cav1.2 mechanism in neuropsychiatric-related endophenotypes and a potential

261 emerged, describing chronic neurological and neuropsychiatric sequelae occurring in former boxers.

262 Neuropsychiatric signs and symptoms occur frequently in

263 asculitis or a leukodystrophy with prominent neuropsychiatric signs or dementia.

264 Using neuropsychiatric single-nucleotide polymorphism (SNP) an

265 Neuropsychiatric status was assessed using the Hamilton

266 evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neurops

267 lder adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD.

268 Increases in pain were associated with worse neuropsychiatric symptom scores within all groups.

269 exercise intervention significantly improved neuropsychiatric symptoms (-3.59, 95% CI -7.08 to -0.09)

270 Secondary outcome measures were overall neuropsychiatric symptoms and mortality.

271 ury, autoimmune disorders, and infections to neuropsychiatric symptoms and suicidality is only beginn

272 Neuropsychiatric symptoms in addition to schizophrenia,

273 increased prevalence and early emergence of neuropsychiatric symptoms in patients with dementia with

274 nts is associated with the severity of these neuropsychiatric symptoms is unknown.

275 x behaviours as a 'lesion-based' approach to neuropsychiatric symptoms observed across diagnostic cat

276 stimulation in psychiatric disorders and the neuropsychiatric symptoms of Parkinson's disease, these

277 remains difficult to accurately elucidate if neuropsychiatric symptoms or conditions are indicators o

278 The authors sought to determine which neuropsychiatric symptoms predict relapse.

279 y, up to 75% of patients with SLE experience neuropsychiatric symptoms that range from anxiety, depre

280 n Cognitive Decline in the Elderly (IQCODE); neuropsychiatric symptoms were evaluated using the Neuro

281 Neuropsychiatric symptoms were rated using the Beck Depr

282 adults, their correlation with cognitive and neuropsychiatric symptoms, and the accuracy of dementia

283 lse Control disorders And the association of neuRopsychiatric symptoms, cognition and qUality of life

284 withdrawal symptoms) and clinical outcomes (neuropsychiatric symptoms, cognitive function, and quali

285 Neuropsychiatric symptoms, depressive symptoms in partic

286 imer's disease (AD) is associated with other neuropsychiatric symptoms, including severe depression.

287 e disorder (OCD) cases exhibiting additional neuropsychiatric symptoms, it was proposed that neuroinf

288 d with respect to behavioural, cognitive and neuropsychiatric symptoms.

289 s for gastrointestinal, musculoskeletal, and neuropsychiatric symptoms.

290 g NFL athletes are related to later onset of neuropsychiatric symptoms.

291 3 may serve as a target for the treatment of neuropsychiatric symptoms.

292 by which a single lesion can cause a complex neuropsychiatric syndrome based on that lesion's unique

293 tial case descriptions were of a progressive neuropsychiatric syndrome with abnormalities of mood, sl

294 diagnostic concept of pediatric acute-onset neuropsychiatric syndrome.

295 In this review, we discuss the common neuropsychiatric syndromes that occur in MS and describe

296 que compared with lesions causing four other neuropsychiatric syndromes.

297 transfer imaging, show some correlation with neuropsychiatric systemic lupus erythematosus (NPSLE) sy

298 genic risk scores identified pleiotropy with neuropsychiatric traits and brain volumes.

299 ether polygenic risk alleles are shared with neuropsychiatric traits or subcortical brain volumes.

300 anges in 16p11.2 contribute significantly to neuropsychiatric traits.